ABOUT

We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.

We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.

We envision a world where neurodegenerative diseases are prophylactically eradicated.

MORE ABOUT US

By The Numbers

80 years ago, it was polio. Today, our epidemic is Alzheimer’s.

50%

CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD

100%

FATAL

$1 TRILLION

ANNUAL COST TO THE WORLD

Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.

OUR SCIENCE

We aren’t your average vaccine company.

We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.

HOW OUR VACCINES ARE DIFFERENT

NEWS

United Neuroscience To Move Forward Alzheimer’s Vaccine After Promising Phase IIa

January 17, 2019 -

Private, Dublin-based biotech United Neuroscience says it plans to rapidly advance its active Alzheimer's vaccine immunotherapy UB-311 after reporting positive top-line results from a Phase IIa study of 42 patients on Jan. 16.

Read More

United Neuro seeks ‘cautiously optimistic’ next step with AD vaccine candidate

January 17, 2019 -

United Neuroscience Ltd. posted top-line results from a phase IIa study of UB-311, its synthetic peptide vaccine candidate targeting beta-amyloid (A-beta) for the treatment of Alzheimer's disease (AD), showing the effort met the primary aims of safety and immunogenicity with a 96 percent response rate. 

Read More

JOIN US

Does achieving the seemingly impossible inspire you? Would you describe yourself as passionate and ambitious? We are constantly looking for dedicated people who enjoy developing breakthrough programs to join our team.

EXPLORE OUR OPPORTUNITIES